BNTX Form 144 Filed for 1,774,837 ADSs Worth $200M

Rhea-AI Filing Summary

Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Clear provenance of shares: The filing specifies the shares were acquired via stock option exercises on 11/21/2022 and 08/09/2024, providing transparency on origin.
• Broker identified: Berenberg Capital Markets LLC is named, giving a clear execution channel for the proposed sale.

Negative

• Large block size: The proposed sale totals 1,774,837 ADSs with aggregate market value of $200,024,129.90, which could increase share supply on the sale date.
• Potential near-term selling pressure: The specified approximate sale date is 08/15/2025, concentrating supply on a single day (as reported).

Insights

Securities Analyst

TL;DR: A planned sale of 1.77M ADSs valued at ~$200M is reported; timing and size are material to share supply but not a change in issuer operations.

The filing documents a single proposed transaction executed through a broker on 08/15/2025 for 1,774,837 ADSs with an aggregate market value of $200,024,129.90. The underlying shares were obtained by stock option exercises in 2022 and 2024, indicating these are insider/beneficiary-originated shares rather than newly issued stock. No sales in the prior three months are reported, and the seller provides the standard representation regarding material nonpublic information. From a market-impact perspective, the block size is explicit; assessing pricing pressure requires market depth data not present in the filing.

Corporate Governance Expert

TL;DR: The notice is a routine required disclosure of a proposed sale under Rule 144, documenting source and broker details.

The form lists Berenberg Capital Markets LLC as the broker and records acquisition details (stock option exercises on 11/21/2022 and 08/09/2024) for a total of 1,774,837 ADSs to be sold. The filing includes the attestations required by the form, including the statement that the seller is unaware of undisclosed material adverse information. There are no governance events, legal disclaimers beyond standard warnings, or other corporate actions disclosed in this submission.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Berenberg Capital Markets LLC 1251 Avenue of the Americas 53rd Floor New York NY 10020	1774837	200024129.90	240398724	08/15/2025	Nasdaq Global Select

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	08/09/2024	Stock Option Exercise	BioNTech SE			918651	08/09/2024	Stock Option Exercise
Ordinary Shares, no par value per share	11/21/2022	Stock Option Exercise	BioNTech SE			856186	11/21/2022	Stock Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for BioNTech (BNTX) disclose?

It discloses a proposed sale of 1,774,837 ADSs with an aggregate market value of $200,024,129.90, to be executed via Berenberg Capital Markets LLC on 08/15/2025.

How were the shares being sold by the filer acquired?

The underlying ordinary shares were acquired by stock option exercises11/21/2022 (856,186 shares) and 08/09/2024 (918,651 shares).

Does the filing report any sales in the prior three months for the seller?

No. The filing states "Nothing to Report"

Which exchange will the ADSs be sold on?

Nasdaq Global Select

Who is the broker handling the proposed sale?

Berenberg Capital Markets LLC